Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 28;58(5):612.
doi: 10.3390/medicina58050612.

Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies

Aikaterini Foska  1 , Ioanna Tsantzali  1 , Eleni Sideri  1 , Maria Ioanna Stefanou  1 , Eleni Bakola  1 , Dimitrios K Kitsos  1 , Christina Zompola  1 , Anastasios Bonakis  1 , Sotirios Giannopoulos  1 , Konstantinos I Voumvourakis  1 , Georgios Tsivgoulis  1 , George P Paraskevas  1
Affiliations

Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies

Aikaterini Foska et al. Medicina (Kaunas). .

Abstract

The use and interpretation of diagnostic cerebrospinal fluid (CSF) biomarkers for neurodegenerative disorders, such as Dementia with Lewy bodies (DLB), represent a clinical challenge. According to the literature, the composition of CSF in DLB patients varies. Some patients present with reduced levels of amyloid, others with full Alzheimer Disease CSF profile (both reduced amyloid and increased phospho-tau) and some with a normal profile. Some patients may present with abnormal levels of a-synuclein. Continuous efforts will be required to establish useful CSF biomarkers for the early diagnosis of DLB. Given the heterogeneity of methods and results between studies, further validation is fundamental before conclusions can be drawn.

Keywords: Alzheimer’s disease; Dementia with Lewy bodies; a-synuclein; beta-amyloid; biomarkers; cerebrospinal fluid; phospho-tau; tau.

PubMed Disclaimer

Conflict of interest statement

G.P.P. has received fees from Biogen International as a consultant on the advisory board. All other authors none.

References

    1. McKeith I.G., Boeve B.F., Dickson D.W., Halliday G., Taylor J.P., Weintraub D., Aarsland D., Galvin J., Attems J., Ballard C.G., et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100. doi: 10.1212/WNL.0000000000004058. - DOI - PMC - PubMed
    1. Vekrellis K., Xilouri M., Emmanouilidou E., Rideout H.J., Stefanis L. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015–1025. doi: 10.1016/S1474-4422(11)70213-7. - DOI - PubMed
    1. Shahmoradian H.S., Lewis J.A., Genoud C., Hench J., Moors E.T., Navarro P.P., Castaño-Díez D., Schweighauser G., Graff-Meyer A., Kenneth N.G., et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 2019;22:1099–1109. doi: 10.1038/s41593-019-0423-2. - DOI - PubMed
    1. Hilal A.L. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. Neurobiol. Dis. 2020;141:104876. - PubMed
    1. Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., DeKosky S.T., Gauthier S., Selkoe D., Bateman R., et al. Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. Lancet Neurol. 2014;13:614–629. doi: 10.1016/S1474-4422(14)70090-0. - DOI - PubMed

MeSH terms